Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research and development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. Its product portfolio includes Mou… Read more
Staidson Beijing Biopharma (300204) - Net Assets
Latest net assets as of September 2025: CN¥859.70 Million CNY
Based on the latest financial reports, Staidson Beijing Biopharma (300204) has net assets worth CN¥859.70 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.26 Billion) and total liabilities (CN¥404.22 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥859.70 Million |
| % of Total Assets | 68.02% |
| Annual Growth Rate | 21.41% |
| 5-Year Change | -42.25% |
| 10-Year Change | -45.55% |
| Growth Volatility | 133.19 |
Staidson Beijing Biopharma - Net Assets Trend (2007–2024)
This chart illustrates how Staidson Beijing Biopharma's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Staidson Beijing Biopharma (2007–2024)
The table below shows the annual net assets of Staidson Beijing Biopharma from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥916.76 Million | -10.18% |
| 2023-12-31 | CN¥1.02 Billion | -24.61% |
| 2022-12-31 | CN¥1.35 Billion | -12.70% |
| 2021-12-31 | CN¥1.55 Billion | -2.32% |
| 2020-12-31 | CN¥1.59 Billion | -2.92% |
| 2019-12-31 | CN¥1.64 Billion | -33.47% |
| 2018-12-31 | CN¥2.46 Billion | +11.25% |
| 2017-12-31 | CN¥2.21 Billion | +15.18% |
| 2016-12-31 | CN¥1.92 Billion | +13.93% |
| 2015-12-31 | CN¥1.68 Billion | +11.19% |
| 2014-12-31 | CN¥1.51 Billion | +15.25% |
| 2013-12-31 | CN¥1.31 Billion | +5.90% |
| 2012-12-31 | CN¥1.24 Billion | +12.59% |
| 2011-12-31 | CN¥1.10 Billion | +562.99% |
| 2010-12-31 | CN¥166.23 Million | +38.85% |
| 2009-12-31 | CN¥119.72 Million | +90.58% |
| 2008-12-31 | CN¥62.82 Million | +85.46% |
| 2007-12-31 | CN¥33.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Staidson Beijing Biopharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 39223964284.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥477.77 Million | 51.42% |
| Other Comprehensive Income | CN¥415.73 Million | 44.74% |
| Other Components | CN¥454.51 Million | 48.91% |
| Total Equity | CN¥929.23 Million | 100.00% |
Staidson Beijing Biopharma Competitors by Market Cap
The table below lists competitors of Staidson Beijing Biopharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mercialys
PINK:MEIYF
|
$955.20 Million |
|
CRISIL Limited
NSE:CRISIL
|
$955.46 Million |
|
Chongqing Three Gorges Water Conservancy and Electric Power Co Ltd
SHG:600116
|
$955.67 Million |
|
InterRent Real Estate Investment Trust
PINK:IIPZF
|
$955.74 Million |
|
Huapont Life Sciences Co Ltd
SHE:002004
|
$954.57 Million |
|
MY EG Services Bhd
KLSE:0138
|
$954.57 Million |
|
Ninety One Group
PINK:NINTF
|
$954.35 Million |
|
Guodian Nanjing Automation Co Ltd
SHG:600268
|
$954.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Staidson Beijing Biopharma's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,020,667,878 to 929,233,931, a change of -91,433,947 (-9.0%).
- Net loss of 144,842,560 reduced equity.
- Dividend payments of 543,156 reduced retained earnings.
- Other comprehensive income increased equity by 74,306,439.
- Other factors decreased equity by 20,354,670.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-144.84 Million | -15.59% |
| Dividends Paid | CN¥543.16K | -0.06% |
| Other Comprehensive Income | CN¥74.31 Million | +8.0% |
| Other Changes | CN¥-20.35 Million | -2.19% |
| Total Change | CN¥- | -8.96% |
Book Value vs Market Value Analysis
This analysis compares Staidson Beijing Biopharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 221.77x to 13.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.11 | CN¥25.48 | x |
| 2008-12-31 | CN¥0.20 | CN¥25.48 | x |
| 2009-12-31 | CN¥0.36 | CN¥25.48 | x |
| 2010-12-31 | CN¥0.47 | CN¥25.48 | x |
| 2011-12-31 | CN¥2.55 | CN¥25.48 | x |
| 2012-12-31 | CN¥2.65 | CN¥25.48 | x |
| 2013-12-31 | CN¥2.82 | CN¥25.48 | x |
| 2014-12-31 | CN¥3.21 | CN¥25.48 | x |
| 2015-12-31 | CN¥3.55 | CN¥25.48 | x |
| 2016-12-31 | CN¥3.99 | CN¥25.48 | x |
| 2017-12-31 | CN¥4.62 | CN¥25.48 | x |
| 2018-12-31 | CN¥5.13 | CN¥25.48 | x |
| 2019-12-31 | CN¥3.48 | CN¥25.48 | x |
| 2020-12-31 | CN¥3.38 | CN¥25.48 | x |
| 2021-12-31 | CN¥3.27 | CN¥25.48 | x |
| 2022-12-31 | CN¥2.85 | CN¥25.48 | x |
| 2023-12-31 | CN¥2.15 | CN¥25.48 | x |
| 2024-12-31 | CN¥1.94 | CN¥25.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Staidson Beijing Biopharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -44.59%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.24x
- Recent ROE (-15.59%) is below the historical average (5.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 11.11% | 15.61% | 0.29x | 2.43x | CN¥374.29K |
| 2008 | 26.14% | 32.26% | 0.55x | 1.47x | CN¥10.14 Million |
| 2009 | 29.54% | 39.97% | 0.59x | 1.24x | CN¥23.39 Million |
| 2010 | 34.59% | 44.85% | 0.48x | 1.59x | CN¥40.88 Million |
| 2011 | 9.46% | 50.66% | 0.18x | 1.04x | CN¥-5.95 Million |
| 2012 | 12.91% | 28.81% | 0.39x | 1.15x | CN¥36.16 Million |
| 2013 | 8.34% | 12.27% | 0.57x | 1.19x | CN¥-21.83 Million |
| 2014 | 12.90% | 17.87% | 0.60x | 1.20x | CN¥43.84 Million |
| 2015 | 12.68% | 16.91% | 0.60x | 1.24x | CN¥44.55 Million |
| 2016 | 13.53% | 18.33% | 0.60x | 1.24x | CN¥67.06 Million |
| 2017 | 11.91% | 18.95% | 0.53x | 1.19x | CN¥42.09 Million |
| 2018 | 5.45% | 16.63% | 0.29x | 1.13x | CN¥-111.73 Million |
| 2019 | 1.67% | 4.13% | 0.36x | 1.14x | CN¥-136.22 Million |
| 2020 | -8.38% | -31.28% | 0.23x | 1.17x | CN¥-291.77 Million |
| 2021 | -8.86% | -23.52% | 0.32x | 1.18x | CN¥-292.47 Million |
| 2022 | -14.55% | -35.89% | 0.33x | 1.23x | CN¥-332.39 Million |
| 2023 | -39.08% | -109.53% | 0.27x | 1.31x | CN¥-500.96 Million |
| 2024 | -15.59% | -44.59% | 0.28x | 1.24x | CN¥-237.77 Million |
Industry Comparison
This section compares Staidson Beijing Biopharma's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,722,009,584
- Average return on equity (ROE) among peers: 7.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Staidson Beijing Biopharma (300204) | CN¥859.70 Million | 11.11% | 0.47x | $955.18 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $183.33 Million | -11.06% | 0.92x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.03 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $387.30 Million | 7.50% | 0.60x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $248.75 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $860.44 Million |
| Hualan Biological EngineeringInc (002007) | $4.84 Billion | 16.95% | 0.08x | $2.01 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.20 Billion | 4.62% | 0.66x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $763.33 Million | 17.77% | 0.08x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.81 Billion | 11.12% | 0.67x | $414.37 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $3.77 Billion | 15.42% | 0.67x | $347.52 Million |